Bropirimine

Bropirimine is an immunomodulator with diverse biological activities. It is a toll-like receptor 7 (TLR7) agonist that inhibits RANKL-induced osteoclast differentiation of murine bone marrow-derived macrophages (BMDMs) in a concentration-dependent manner, an effect that is reversed by an anti-IFN-beta antibody. Dietary administration of bropirimine (200 mg/kg twice per week) prevents development of transitional cell carcinomas (TCCs) in a mouse model of carcinogen-induced bladder carcinoma. Bropirimine (100 mg/kg) reduces pulmonary collagen accumulation and bronchoalveolar lavage fluid (BALF) monocyte and eosinophil infiltration in a hamster model of bleomycin-induced lung fibrosis. It also delays disease onset and progression and increases plasma IFN levels in a mouse model of experimental autoimmune encephalomyelitis (EAE).Formal Name: 2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone. CAS Number: 56741-95-8. Synonyms: ABPP, NSC 149027, PNU 54461, U-54461. Molecular Formula: C10H8BrN3O. Formula Weight: 266.1. Purity: >95%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 16 mg/ml, DMF:PBS (pH 7.2) (1:1): 0.5 mg/ml, DMSO: 12 mg/ml, Ethanol: 1 mg/ml. lambdamax: 235, 313 nm. SMILES: O=C1C(Br)=C(C2=CC=CC=C2)NC(N)=N1. InChi Code: InChI=1S/C10H8BrN3O/c11-7-8(6-4-2-1-3-5-6)13-10(12)14-9(7)15/h1-5H,(H3,12,13,14,15). InChi Key: CIUUIPMOFZIWIZ-UHFFFAOYSA-N.